Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 282, Issue 3 45-3, 2002, Pages

  Delgado Aros, Silvia ^a   Kim, Doe Young ^a   Burton, Duane D ^a   Thomforde, George M ^a   Stephens, Debra ^a   Brinkmann, Benjamin H ^a   Vella, Adrian ^a   Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

Accommodation; Diabetes; Satiation; Single photon emission computed tomography; Vagus

Indexed keywords

ENSURE; GLUCAGON LIKE PEPTIDE 1; PANCREAS POLYPEPTIDE;

ADULT; ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; HUNGER; MAXIMUM TOLERATED DOSE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH EMPTYING; STOMACH VOLUME; SYMPTOM; TEST MEAL; VAGUS TONE;

EID: 0036086315     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.2002.282.3.g424     Document Type: Article

References (46)

1. SPECT test to measure gastric accommodation validated with simultaneous barostat measurement
2. Role of nitric oxide in fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus
3. Reliability of a semi-automated analysis to measure gastric accommodation using SPECT in humans
4. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
5. Impaired accommodation of proximal stomach to a meal in functional dyspepsia
6. Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate
7. Antidiabetogenic effect of glucagon-like peptide-1(7-36) amide in normal subjects and patients with diabetes mellitus
8. Glucagon-like peptide-1: A potent regulator of food intake in humans
9. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
10. Gastric emptying of liquids and solids: Roles of proximal and distal stomach
11. Can plasma human pancreatic polypeptide be used to detect diseases of the exocrine pancreas?
12. Glucagon-like peptide-1 7-36: A physiological incretin in man
13. Development of a test to measure gastric accommodation in humans
14. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
15. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
16. The relationship between technetium-99m pertechnetate gastric scanning and gastric contents
17. Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagon-like peptide-1 7-37 in healthy subjects are indistinguishable
18. Antroduodenal motor response to solid, liquid and homogenized meals
19. Peripheral vs. central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
20. Meckel's diverticulum: Imaging diagnosis
21. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans
22. Responses to gastric distension in functional dyspepsia
23. Proximal gastric motor activity in response to a liquid meal in type I diabetes mellitus with autonomic neuropathy
24. Compliance of the proximal stomach and dyspeptic symptoms in patients with type I diabetes mellitus
25. Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition
26. Effects of glucagon-like peptide-1(7-36)amide on antropyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
27. Gastric emptying and release of incretin hormones after glucose ingestion in humans
28. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men
29. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus
30. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
31. Nitric oxide and gastric relaxation
32. Pancreatic polypeptide: A hormone under vagal control
33. Role of impaired gastric accommodation to a meal in functional dyspepsia
34. 2-adrenergic agents in humans
35. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
36. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones
37. Effect of glyceryl trinitrate on proximal stomach musculature in normal volunteers
38. Reproducibility of a water load test in healthy subjects and symptom profile compared to patients with functional dyspepsia
39. A role for glucagon-like peptide-1 in the central regulation of feeding
40. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes
41. Effects of GLP-1 on proximal gastric motor and sensory function in human
42. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man
43. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
44. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
45. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation
46. Effect of proximal gastric, complete gastric, and truncal vagotomy on canine gastric electric activity, motility, and emptying